Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.…
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics (NASDAQ: STOK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 170 employees.
The shares were at 26.81 USD on 20 November 2026, up 17.3% over 52 weeks. Its 52-week range is 21.81 USD to 40.22 USD: the price is 33.3% below the high and 22.9% above the low.
Its market capitalisation is 1.75B USD.
Stoke Therapeutics reports return on equity of -2.0% and revenue up 5.9% year over year.
It holds more cash than debt, a net cash position of 317.27M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 46.38 USD is 73.0% above the current price. The next earnings report is expected on 15 March 2027.